1301 Harbor Bay Parkway
437 articles with BioTime, Inc.
Announced Rebranding and Name Change to Lineage Cell Therapeutics and Corporate Relocation
BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019
BioTime management will also host a conference call and webcast on Thursday, August 8th, 2019, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2019 financial results and to provide a business update.
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it is launching a new corporate brand, including a change of its corporate name to Lineage Cell Therapeutics, Inc., effective August 12, 2019
BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System
The primary objective of the Phase I/IIa study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, announced the pricing of the sale of 2,250,000 shares of common stock of OncoCyte Corporation at a price to buyers of $2.00 per share, for gross proceeds totaling $4,500,000, before payment of customary sales commissions and offering expenses.
Today announced that it has appointed Chase C. Leavitt as BioTime’s General Counsel and Corporate Secretary.
BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
BioTime, Inc., a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant for 2019 of up to 9 million Israeli New Shekels from the Israel Innovation Authority.
BioTime, Inc. reported financial and operating results for the first quarter ended March 31, 2019.
BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury
The issued patent would have a term that expires no earlier than 2036.
BioTime, Inc. announced that it will report its first quarter 2019 financial and operating results on Thursday, May 9th, 2019, following the close of the U.S. financial markets.
BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
Treatment with OpRegen® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina Observed in Some Patients
BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference
BioTime, Inc. announced that Edward D. Wirth, III, M.D., Ph.D., Chief Medical Officer of BioTime, will present at the 26th Annual American Society for Neural Therapy and Repair (ASNTR) Annual Conference on April 26th, 2019 at 10:30am EDT as part of Session 6: “Spinal Cord Injury”.
BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical study of its lead product candidate, OpRegen
BioTime, Inc. announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 20th, 2019 at 2:45pm Eastern Time at the Westin New York Grand Central in the Track 2 Room in New York, NY.
BioTime, Inc., a clinical-stage biotechnology company focused on degenerative diseases, reported financial and operating results for the fourth quarter and full year ended December 31, 2018.
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the 2019 Biotech Showcase Investor Conference on January 7th, 2019 at 9am Pacific Time at the Hilton San Francisco Union Square Hotel in the Franciscan A Ballroom in San Francisco, CA.
BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the publication of positive preclinical results which demonstrate that targeted intracerebral delivery of brain-derived neurotrophic factor utilizing HyStem
Distribution to Commence Today at 5:00pm ET
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Industry Veteran Brian M. Culley Appointed as CEO